Gilead Sciences in charts: Q2 base sales jump 10% on HIV, oncology growth despite Veklury drop

Gilead Sciences reported solid performance in the second quarter, with growth in its HIV and oncology segments.

AI CATALYST SCORE75 / 100Score computed by Sentinel V12

REFERENCE PRICENot measuredReference entry price at analysis time

ANALYSIS HISTORY

GILD Analysis History (Last 30 Days)

Diagnosed At	Ticker	AI Score	Tier
2026-08-24 11:23:17	GILD	85	Mid	View Report →
2026-08-05 09:00:48	GILD	78	Mid	View Report →
2026-08-05 05:07:00	GILD	75	Mid	View Report →

RELATED REPORTS

Diagnosed At	Ticker	AI Score	Tier
2026-08-26 12:00:16	SMMT	85	S-Class	View Report →
2026-08-26 11:33:57	LLY	85	Mid	View Report →
2026-08-26 11:33:56	JAZZ	50	Row	View Report →
2026-08-25 18:53:31	APRE	85	S-Class	View Report →
2026-08-25 14:51:51	JAZZ	85	S-Class	View Report →
2026-08-25 14:26:29	MRNA	90	S-Class	View Report →
2026-08-25 14:21:10	LLY	40	Row	View Report →
2026-08-25 13:22:05	LLY	75	Mid	View Report →
2026-08-25 12:33:09	CAPR	85	S-Class	View Report →
2026-08-25 10:34:43	MRK	85	S-Class	View Report →
2026-08-25 10:05:37	MRNA	75	Mid	View Report →
2026-08-25 07:25:11	AMIX	90	Mid	View Report →
2026-08-24 18:45:22	ALVO	85	S-Class	View Report →
2026-08-24 17:17:01	MRNA	85	S-Class	View Report →
2026-08-24 16:11:14	LLY	75	Mid	View Report →
2026-08-24 15:20:12	ARGX	40	Row	View Report →
2026-08-24 14:30:55	CAPR	85	S-Class	View Report →
2026-08-24 13:47:35	ETON	85	S-Class	View Report →
2026-08-24 12:44:24	LXRX	85	S-Class	View Report →
2026-08-24 11:50:04	RGNX	45	Row	View Report →
2026-08-23 13:48:35	FBRX	50	Row	View Report →
2026-08-22 22:04:03	MRNA	85	S-Class	View Report →
2026-08-22 03:43:04	MRNA	85	S-Class	View Report →
2026-08-21 23:48:12	OMER	35	Row	View Report →
2026-08-21 21:34:43	HIMS	40	Row	View Report →
2026-08-21 18:06:57	NUVB	85	Mid	View Report →
2026-08-21 15:15:20	NUVB	75	Mid	View Report →
2026-08-21 14:07:00	TGTX	75	Mid	View Report →
2026-08-21 12:56:23	HOWL	90	S-Class	View Report →
2026-08-21 12:12:45	HOWL	85	S-Class	View Report →